# Berberastine (found in Hydrastis canadensis and Phellodendron species)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/berberastine-found-in-hydrastis-canadensis-and-phellodendron-species
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** 5,6-dihydro-9,10-dimethoxy-1,3-dioxolo[4,5-g]isoquinolinium (structural descriptor), Berberastine (found in Coptis japonica, Hydrastis canadensis, Phellodendron amurense), goldenseal minor alkaloid, berberastine alkaloid, protoberberine-class alkaloid

## Overview

Berberastine is a protoberberine alkaloid that, while lacking significant standalone [antimicrobial](/ingredients/condition/immune-support) activity, contributes to the synergistic antimicrobial potency of goldenseal extracts by co-occurring with efflux-pump-modulating synergists that reduce berberine's minimum inhibitory concentration against Staphylococcus aureus from 150 μg/mL to as low as 2.3 μg/mL. Its primary clinical relevance to date derives from its role as a biomarker compound for goldenseal botanical identity verification and its participation in the broader alkaloid matrix of plants with established antimicrobial and antidiabetic pharmacology.

## Health Benefits

- **[Antimicrobial](/ingredients/condition/immune-support) Synergy Contribution**: Berberastine co-occurs in goldenseal fractions containing bioactive synergists (including sideroxylin derivatives) that potentiate berberine's antibacterial action, reducing the MIC against S. aureus from 150 μg/mL to 2.3 μg/mL in fraction-level studies; berberastine itself does not exhibit standalone antibacterial activity but is part of the synergistic alkaloid complex.
- **Botanical Authentication Marker**: Berberastine serves as a validated phytochemical biomarker for confirming the identity and quality of goldenseal (Hydrastis canadensis) preparations, enabling distinction from adulterants in analytical workflows using HPLC and LC-MS platforms.
- **Antidiabetic Context via Associated Alkaloid Matrix**: In Phellodendri Cortex preparations, berberastine is part of an alkaloid-rich extract that includes berberine, a compound with well-documented AMP-kinase activation and glucose-lowering properties; berberastine's contribution to this antidiabetic activity is presumed synergistic but not independently quantified.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Potential (Indirect)**: The plant matrices containing berberastine, particularly Phellodendri Cortex, contain over 140 identified compounds including flavonoids, phenolic acids, and limonoids with known anti-inflammatory mechanisms; berberastine's independent contribution to inflammation modulation has not been isolated in controlled study designs.
- **Gastrointestinal Support via Host Plant Pharmacology**: Traditional preparations of goldenseal and Phellodendron bark, in which berberastine is a resident alkaloid, have long been used for gastrointestinal infections and mucosal support; these effects are attributed primarily to berberine and hydrastine, with berberastine contributing to the overall protoberberine activity profile.
- **Phytochemical Diversity as Bioactive Reservoir**: Berberastine's structural classification as a protoberberine alkaloid places it in a class with confirmed bioactivity across multiple molecular targets including DNA topoisomerase inhibition and NF-κB modulation, though direct evidence for berberastine at these targets has not been independently published.

## Mechanism of Action

Berberastine has not been ascribed a clearly characterized standalone mechanism of action at the molecular level in peer-reviewed literature as of current reporting. Within the protoberberine alkaloid class, structurally related compounds such as berberine exert effects through AMPK activation, inhibition of [mitochondrial](/ingredients/condition/energy) complex I, [NF-κB](/ingredients/condition/inflammation) pathway suppression, and intercalation with bacterial DNA gyrase and topoisomerase IV; berberastine's closely related isoquinoline scaffold suggests possible engagement of overlapping targets, though this remains speculative without direct binding assays. In goldenseal [antimicrobial](/ingredients/condition/immune-support) fractionation research, berberastine-containing fractions exhibited synergistic activity alongside sideroxylin derivatives and a compound designated 'compound 29,' collectively reducing berberine's IC50 from 132.2 ± 1.1 μM to 91.5 ± 1.1 μM, a result attributed to additive or synergistic modulation of bacterial efflux systems or membrane permeability, though the precise molecular target of berberastine within this interaction has not been deconvoluted. Future mechanistic studies employing isolated berberastine in enzyme inhibition assays, bacterial efflux pump models, and receptor binding panels would be required to assign definitive molecular targets.

## Clinical Summary

No clinical trials have been conducted specifically evaluating berberastine as an isolated therapeutic agent; all available data derives from in vitro phytochemical studies and extract-level [antimicrobial](/ingredients/condition/immune-support) assays using goldenseal and Phellodendron-based preparations. The most relevant clinical context is the broader evidence base for goldenseal and Phellodendri Cortex preparations, within which berberastine is a minor constituent, and for berberine specifically, which shares berberastine's protoberberine scaffold and has been evaluated in multiple RCTs for type 2 diabetes and dyslipidemia. Confidence in berberastine-specific therapeutic effects is very low, as no effect sizes, patient outcomes, or controlled dose-response data exist for this compound in isolation. Until targeted clinical investigation is conducted, berberastine's clinical relevance remains contingent on its role within the polypharmacological matrix of the source plants rather than as a standalone clinical ingredient.

## Nutritional Profile

Berberastine is a pure alkaloid compound (molecular formula C₂₀H₁₉NO₄, molecular weight approximately 341.37 g/mol) and does not contribute macronutrients, vitamins, or dietary minerals in any physiologically meaningful quantity; it functions as a secondary metabolite rather than a nutrient. In goldenseal root extracts, berberastine occurs at analytically detectable but minor concentrations relative to major alkaloids — berberine is present at approximately 73.0 μg/mL, hydrastine at 93.6 μg/mL, and berberastine at levels sufficient for LC-MS detection but not yet independently quantified in absolute mass concentration in published extraction studies. The broader phytochemical context of its source plants includes flavonoids, phenolic acids (including chlorogenic acid in Phellodendron), lignans, limonoids, quinic acid derivatives, and other isoquinoline alkaloids — a phytochemical diversity of approximately 140 identified compounds in Phellodendri Cortex species — all of which influence the overall bioactivity of preparations containing berberastine. Bioavailability of protoberberine alkaloids as a class is generally low due to P-glycoprotein-mediated efflux and first-pass hepatic [metabolism](/ingredients/condition/weight-management), a limitation likely applicable to berberastine given its structural similarity to berberine, though no direct berberastine pharmacokinetic data has been published.

## Dosage & Preparation

- **Standardized Goldenseal Root Extract**: Berberastine is present as a minor constituent; typical goldenseal supplements are standardized to 5–10% total alkaloids (primarily berberine and hydrastine at 200–500 mg/day); no berberastine-specific standardization exists.
- **Phellodendri Cortex (Huang Bai) Decoction**: Traditional preparation involves boiling dried bark (3–12 g) in water; berberastine is co-extracted alongside berberine and phellodendrine, though it is not dosed independently.
- **Hydroalcoholic Tincture (Goldenseal)**: Root material extracted in 60–70% ethanol captures the full protoberberine alkaloid profile including berberastine; typical tincture doses range from 2–4 mL (1:5 extract) up to three times daily for the parent herb preparation.
- **Ambient Solvent Fractionation (Research Use)**: Analytical studies employ 20-minute ambient solvent extraction methods to fractionate goldenseal alkaloids including berberastine for bioassay purposes; this method is not a commercial supplementation format.
- **No Isolated Berberastine Supplement Form**: Berberastine is not currently available as a standalone commercial supplement; consumers accessing berberastine receive it only as part of whole-plant or full-spectrum alkaloid goldenseal or Phellodendron preparations.
- **Timing Note**: For parent-plant preparations, traditional use and current practice suggest administration with or shortly before meals to maximize gastrointestinal alkaloid absorption and minimize gastric irritation.

## Safety & Drug Interactions

No berberastine-specific toxicity data, adverse event profiles, or maximum safe dose thresholds have been established in the published literature, as the compound has not been studied in isolation in animal or human safety trials. Safety inferences are drawn from its parent plants: goldenseal preparations are generally considered safe at typical supplemental doses for short-term use but are contraindicated in pregnancy due to potential uterotonic effects of hydrastine and berberine, and Phellodendri Cortex is used cautiously in individuals with spleen and stomach deficiency according to traditional Chinese medical practice. Drug interaction risks associated with berberastine-containing plant preparations are primarily attributed to berberine, which inhibits CYP3A4 and P-glycoprotein and may potentiate anticoagulants (warfarin), antidiabetic agents (insulin, metformin), and antihypertensive medications; these interactions should be assumed relevant for whole-plant goldenseal and Phellodendron products containing berberastine until compound-specific data becomes available. Lactating individuals, immunocompromised patients, and those on narrow therapeutic index medications should consult a qualified healthcare provider before using berberastine-containing botanical preparations.

## Scientific Research

The scientific evidence base for berberastine as an isolated compound is extremely limited, consisting primarily of phytochemical characterization studies and alkaloid profiling rather than controlled pharmacological experiments. In vitro fractionation studies of goldenseal (Hydrastis canadensis) have demonstrated that berberastine-containing fractions participate in synergistic [antimicrobial](/ingredients/condition/immune-support) activity, with one study showing fraction GS-4 reducing berberine's MIC against Staphylococcus aureus from 150 μg/mL to 18.8 μg/mL, though berberastine's specific mechanistic contribution was not isolated from other co-occurring synergists in the fraction. Analytical studies using LC-MS and HPLC have quantified berberastine in goldenseal root extracts alongside berberine (73.0 μg/mL), hydrastine (93.6 μg/mL), palmatine (94.4 μg/mL), canadine (98.8 μg/mL), and hydrastinine (83.3 μg/mL), confirming its role as a phytochemical identity marker rather than a primary pharmacological agent. No human clinical trials, animal pharmacokinetic studies, or randomized controlled trials specifically investigating berberastine as an isolated intervention have been identified in the current literature, placing it firmly in the category of a preclinical/phytochemical-characterization stage compound.

## Historical & Cultural Context

Goldenseal (Hydrastis canadensis), one of berberastine's primary botanical sources, has a well-documented history of use among Native American peoples, particularly the Cherokee and Iroquois nations, who employed rhizome preparations as a bitter digestive tonic, wound treatment, and eye wash, with these applications later adopted into 19th-century Eclectic medicine in North America. Phellodendron bark (Huang Bai) has been used in Traditional Chinese Medicine for over two millennia, appearing in classical texts including the Shennong Bencao Jing, where it was prescribed as a heat-clearing, dampness-drying herb for conditions including jaundice, dysentery, and [inflammatory](/ingredients/condition/inflammation) disorders — applications now partially attributed to its rich protoberberine alkaloid content. Berberastine as a distinct chemical entity was not identified or conceptualized in these traditional systems; its recognition emerged from 20th-century phytochemical analysis of these plants, and its presence in both Asian and North American medicinal traditions reflects convergent ethnobotanical utilization of protoberberine-containing barks and roots across cultures. The isolation and characterization of berberastine as a biomarker compound represents a modern analytical refinement rather than a traditional therapeutic tradition in its own right.

## Synergistic Combinations

Within goldenseal fractionation research, berberastine co-occurs with sideroxylin-class flavonoids and structurally uncharacterized synergists (including 'compound 29') that together reduce berberine's MIC against Staphylococcus aureus by up to 65-fold (from 150 μg/mL to 2.3 μg/mL), suggesting that the full protoberberine-plus-flavonoid alkaloid complex of goldenseal functions as a synergistic antibacterial stack more potent than any single constituent. In Phellodendri Cortex preparations, berberastine co-exists with chlorogenic acid, phellodendrine, and berberine, compounds with complementary [anti-inflammatory](/ingredients/condition/inflammation) and glucose-lowering activities that may produce additive effects through divergent molecular targets (AMPK activation, NF-κB inhibition, and [antioxidant](/ingredients/condition/antioxidant) pathway induction). The combination of berberastine-containing goldenseal extract with other protoberberine-source plants such as Oregon grape (Berberis aquifolium) or barberry (Berberis vulgaris) represents a traditional stacking approach for gastrointestinal [antimicrobial](/ingredients/condition/immune-support) support, though no controlled synergy studies for berberastine specifically within these combinations have been published.

## Frequently Asked Questions

### What is berberastine and where does it come from?

Berberastine is a minor protoberberine alkaloid found naturally in the roots and rhizomes of goldenseal (Hydrastis canadensis) and in the bark of Phellodendron chinensis and Phellodendron amurense. It belongs to the same isoquinoline alkaloid family as berberine, with which it co-occurs in these medicinal plants, and is present at analytically detectable but relatively low concentrations compared to the dominant alkaloids in these species.

### Does berberastine have antimicrobial properties on its own?

Berberastine does not demonstrate significant standalone antimicrobial activity against organisms such as Staphylococcus aureus in published in vitro studies. However, it is part of the goldenseal alkaloid-flavonoid complex that collectively potentiates berberine's antibacterial activity, with synergistic fractions reducing berberine's minimum inhibitory concentration from 150 μg/mL to as low as 2.3 μg/mL, representing a 65-fold enhancement.

### Can I buy berberastine as a standalone supplement?

Berberastine is not currently available as an isolated commercial supplement and is not sold as a standalone ingredient in the mainstream nutritional products market. Consumers who wish to access berberastine do so indirectly through standardized goldenseal root extracts or Phellodendri Cortex (Huang Bai) preparations, where it occurs alongside berberine and other protoberberine alkaloids.

### How is berberastine different from berberine?

Both berberastine and berberine are protoberberine isoquinoline alkaloids that co-occur in goldenseal and Phellodendron species, but berberine is the dominant, pharmacologically well-characterized compound with extensive clinical trial data for type 2 diabetes, dyslipidemia, and antimicrobial activity. Berberastine is a minor constituent with no standalone clinical trial data; its significance lies in contributing to synergistic activity of the whole-plant alkaloid complex and in serving as an analytical identity marker for goldenseal quality verification.

### Is berberastine safe during pregnancy?

There is no berberastine-specific safety data for pregnancy; however, preparations containing berberastine — including goldenseal and Phellodendron bark products — are contraindicated during pregnancy due to the uterotonic and potentially teratogenic properties associated with berberine and hydrastine co-occurring in these plants. Pregnant individuals should avoid all goldenseal and Phellodendron-based supplements unless under direct supervision of a qualified healthcare provider.

### Does berberastine contribute to the antimicrobial effects of goldenseal extract?

Berberastine does not exhibit standalone antibacterial activity, but it is part of the synergistic alkaloid complex in goldenseal that enhances berberine's antimicrobial potency. In whole-fraction studies, goldenseal preparations containing berberastine alongside other compounds like sideroxylin derivatives have demonstrated dramatically improved antibacterial efficacy, reducing the MIC (minimum inhibitory concentration) against S. aureus from 150 μg/mL to 2.3 μg/mL. This synergistic effect means berberastine's value lies in its co-occurrence with other bioactives rather than isolated action.

### Why is berberastine important in Phellodendron and goldenseal formulations if it has no direct antimicrobial action?

Berberastine functions as part of a synergistic alkaloid matrix that potentiates the effects of berberine and other antimicrobial compounds in these plant species. Its chemical structure and botanical co-location with other bioactive synergists create a combined effect greater than berberine alone could achieve. This explains why whole-plant extracts of Hydrastis canadensis and Phellodendron species are often more effective than isolated berberine supplements in traditional and research applications.

### What research evidence exists for berberastine's role in supplement efficacy?

The strongest evidence for berberastine comes from fraction-level antimicrobial studies showing its contribution to synergistic effects within goldenseal and Phellodendron extracts, rather than from human clinical trials on berberastine alone. Most research focuses on how berberastine participates in alkaloid synergy that enhances berberine's antimicrobial activity against pathogens like S. aureus. Limited independent research exists on berberastine in isolation, making it difficult to establish standalone efficacy claims separate from its synergistic botanical context.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*